The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has delivered two pivotal positive opinions, paving…
Read More
Novo Nordisk hands a Parkinson’s cell therapy to Cellular Intelligence, a startup trying to design cell behavior
Cellular Intelligence, a rapidly emerging biotech firm previously known as Somite AI, has secured global rights to a pioneering clinical-stage…
Read More
Canada approves generic semaglutide from Dr. Reddy’s, a G7 first enabled by Novo Nordisk’s lapsed CAD$250 patent
The Canadian healthcare landscape is poised for a significant transformation with Health Canada’s authorization of Dr. Reddy’s Laboratories’ generic semaglutide…
Read More
Novo Nordisk Hands a Parkinson’s Cell Therapy to Cellular Intelligence, a Startup Trying to Design Cell Behavior
In a significant move poised to reshape the landscape of Parkinson’s disease treatment and the broader cell therapy sector, Cellular…
Read More
Canada Becomes First G7 Nation to Approve Generic Semaglutide Following Novo Nordisk Patent Lapse, Paving Way for Enhanced Access and Affordability
In a landmark decision poised to significantly reshape the pharmaceutical landscape for diabetes and obesity management, Health Canada has granted…
Read More
Novo Nordisk hands a Parkinson’s cell therapy to Cellular Intelligence, a startup trying to design cell behavior
Cellular Intelligence, a burgeoning biotech startup, has announced the acquisition of global rights to a clinical-stage Parkinson’s disease cell therapy,…
Read More
Cellular Intelligence Licenses Novo Nordisk’s Parkinson’s Cell Therapy Program Following Company’s Strategic Pivot
Seven months after Danish pharmaceutical giant Novo Nordisk officially shuttered its dedicated cell therapy unit in October 2025, a significant…
Read More
Novo Nordisk’s Wegovy Pill Fuels Ambitious Growth Strategy Amidst Fierce Competition
Novo Nordisk’s groundbreaking oral semaglutide medication, branded as Wegovy, has emerged as a powerful financial engine, propelling the Danish pharmaceutical…
Read More
Novo Nordisk Launches Oral Ozempic in the US, Revolutionizing Type 2 Diabetes and Cardiovascular Risk Management
The landscape of type 2 diabetes management and cardiovascular risk reduction in the United States has been significantly reshaped with…
Read More
Novo Nordisk’s triple agonist UBT251 delivered up to 19.7% average weight loss in Phase 2 trial
Novo Nordisk, a global leader in diabetes and obesity care, has announced promising results from a Phase 2 trial of…
Read MoreYOU MAY HAVE MISSED
